## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

**[Document Identifier: CMS–R–65 and CMS–10142]**

### Agency Information Collection Activities: Submission for OMB Review; Comment Request

*Correction*

In notice document 2024–30444 beginning in the third column on page 104182 in the issue of Friday, December 20, 2024, make the following correction:

On page 104182, in the third column, under the **DATES** section, replace the text [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE **FEDERAL REGISTER**] with ''January 21, 2025''.

[FR Doc. C1–2024–30444 Filed 1–6–25; 8:45 am]

**BILLING CODE 0099–10–D**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

### Office of Refugee Resettlement

### Statement of Organization, Functions, and Delegations of Authority; Delegation From Office of Refugee Resettlement Director to Unaccompanied Children Bureau Chief

Notice is hereby given that I delegate to the Chief of the Unaccompanied Children Bureau the following authority delegated to the Deputy Assistant Secretary for Humanitarian Services and Director of the Office of Refugee Resettlement by the Assistant Secretary for Children and Families and the Secretary under the William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008 (Pub. L. 110–457 sec. 235, amended).

**(a) Authority Delegated**

Authority under the William Wilberforce Trafficking Victims Protection Reauthorization Act of 2008 section 235(d)(1) to specifically consent to juvenile court jurisdiction for an unaccompanied alien child who is applying for special immigrant status pursuant to the Immigration and Nationality Act (8 U.S.C. 1101 (a)(27)(J)) and who is in the custody of the Secretary.

**(b) Limitations**

1. This delegation shall be exercised under the Department's existing delegation of authority and policy on regulations.

2. This delegation shall be exercised under financial and administrative requirements applicable to all Administration for Children and Families authorities.

**(c) Effective Date**

This delegation of authority is effective on date of signature. In addition, I hereby affirm and ratify any actions taken by the Chief of the Unaccompanied Children Bureau, which, in effect, involved the exercise of these authorities prior to the effective date of this delegation.

**Robin Dunn Marcos,**

*Deputy Assistant Secretary for Humanitarian Services and Director, Office of Refugee Resettlement.*

[FR Doc. 2025–00004 Filed 1–6–25; 8:45 am]

**BILLING CODE 4184–45–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

**[Docket No. FDA–2015–D–3539]**

### Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled ''Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act.'' This guidance describes FDA's interim regulatory policy concerning compounding by outsourcing facilities using bulk drug substances while FDA develops the list of bulk drug substances that outsourcing facilities can use in compounding under the applicable section of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This guidance finalizes the draft guidance of the same title issued in December 2023 and replaces the final guidance of the same title issued in January 2017.

**DATES:** The announcement of the guidance is published in the **Federal Register** on January 7, 2025.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

*Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

*Instructions:* All submissions received must include the Docket No. FDA–2015–D–3539 for ''Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act.'' Received comments will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the